<DOC>
	<DOC>NCT00546923</DOC>
	<brief_summary>To examine the efficacy and safety of venlafaxine XR in the treatment of physical and emotional symptoms in patients with an operationally-defined diagnosis of multisomatoform disorder (MSD).</brief_summary>
	<brief_title>Study Evaluating Venlafaxine Extended-Release in Depressed and Anxious Patients</brief_title>
	<detailed_description>The purpose of this study is to examine the efficacy and safety of venlafaxine XR in the treatment of physical and emotional symptoms in patients with an operationally-defined diagnosis of MSD. Primary efficacy will be evaluated using the PHQ-15 scale, and secondary efficacy will be evaluated using the HAM-D17, HAM-A, CGI, MQOL-PS, VAS and SF-36 evaluation scales. Assessment scales and questionnaires will be administered at specified clinical visits between screening and Week 12 (or discontinuation).</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Â· Subjects must be at least 18 years of age and meet DSMIV diagnostic criteria for major depressive disorder, generalized anxiety disorder, and/ or social anxiety disorder, meet clinical criteria for MSD, have a total score of greater than or equal to 14 on the HAMD17 or a total score of greater than or equal to 12 on the HAMA at screening and no more than a 25% decrease in total HAMD17 score or total HAMA score from screening to randomization. a history of an inability to tolerate or failure to respond to greater than or equal to 2 antidepressants of sufficient dose and duration of administration for the treatment of symptoms present in the current illness; a current or past history of mania, bipolar disorder, schizophrenia, or other psychotic disorder; history of seizure disorder other than childhood febrile seizure; presence of a serious or clinically unstable medical illness or psychiatric condition that would compromise the participation in the study; previous intolerance or hypersensitivity to venlafaxine or venlafaxine XR or nonresponse to a previous adequate trial of any of these drugs, or use of any nonpsychopharmacologic drug with psychotropic effects within 7 days of study randomization; Use of MAOI or fluoxetine within 30 days of screening; or Use of ECT within 3 months of screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>